TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST
Brief Summary: Training patients to alter their own therapy early in the course of a developing exacerbation (self-management) has been shown to improve outcomes in asthma, but there is no good evidence on this for patients with Chronic Obstructive Pulmonary Disease (COPD). Case management, with patients having an identified contact who helps them access care when necessary, has been shown to improve outcomes in recent studies. A combined approach, called supported selfmanagement, may be particularly suitable for this socially and often educationally disadvantaged group of patients.We propose to identify 500 patients at the time of an exacerbation to test this combined strategy in a randomised manner. The primary outcome measure will be readmission to hospital or death due to COPD, important in terms of patient preferences, quality of life and health costs. This will provide important information about intermediate care for COPD patients which should influence service provision within the NHS in Scotland


Options:
A: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program
B: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: adherence to guideline; Type: OTHER; Interventions: Other: Implementation educational programme | Intervention Type: OTHER; Name: Implementation educational programme; Assigned to Arm(s): adherence to guideline
D: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study Of The Safety And Efficacy of 2 Doses Of Tigecycline Versus Imipenem/Cilastatin For The Treatment Of Subjects With Hospital-Acquired Pneumonia
Brief Summary: This study will compare the safety and efficacy of a tigecycline regimen versus an imipenem/cilastatin regimen for the treatment of subjects who are hospitalized with hospital-acquired pneumonia (HAP). At least 70% of enrolled subjects will have ventilator-associated pneumonia (VAP). Two dose levels of tigecycline will be assessed and compared to imipenem/cilastatin in parallel. Subjects will receive intravenous therapy from a minimum of 7 \& up to 14 consecutive days, the exact duration will be at the decision of the investigator based on the subject's condition. Additional protocol specified antibiotics may be given to ensure appropriate coverage. A final assessment at test-of-cure (TOC) visit will be done 10 to 21 days after the last day of therapy. The total duration of subject participation will be between 17 and 44 days, including a follow up period of 30 days after the last day of therapy for SAEs.

Subjects will be followed for safety and efficacy. The safety assessment will include: physical examinations, vital signs, assessment of the clinical signs and symptoms of pneumonia, collection of adverse events, 12-lead ECG, collection of samples for hematology, serum chemistries, and coagulation parameters, \& a serum or urine pregnancy test before study entry for women of childbearing potential. The clinical and microbiological efficacy will both be evaluated.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tigecycline | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tigecycline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: imipenem/cilastatin | Intervention Type: DRUG; Name: tigecycline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: tigecycline; Assigned to Arm(s): B | Intervention Type: DRUG; Name: imipenem/cilastatin; Assigned to Arm(s): C
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: ceftobiprole plus placebo | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: linezolid plus ceftazidime | Intervention Type: DRUG; Name: ceftobiprole plus placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: linezolid plus ceftazidime; Assigned to Arm(s): 002
C: Intervention Type: DRUG; Name: doripenem; Assigned to Arm(s): N/A
D: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization
Brief Summary: The purpose of this study is to determine the size of the benefit of an adjunctive empiric antibiotic therapy compared to standard mechanical debridement and oral hygiene instructions in a representative sample of German periodontitis patients.


Options:
A: Arm Label: test; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin and Metronidazole | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin and Metronidazole; Assigned to Arm(s): test | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
B: Arm Label: clarithromycin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clarithromycin, Other: One-stage full-mouth ultrasonic debridement (FMUD) | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: One-stage full-mouth ultrasonic debridement (FMUD) | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): clarithromycin group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: OTHER; Name: One-stage full-mouth ultrasonic debridement (FMUD); Assigned to Arm(s): clarithromycin group, placebo group
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Scaling and root planing, Drug: Placebos active phase, Drug: Placebos healing phase | Arm Label: Active phase; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Scaling and root planing, Drug: Metronidazole active phase, Drug: Amoxicillin active phase, Drug: Placebos healing phase | Arm Label: Healing phase; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Scaling and root planing, Drug: Metronidazole healing phase, Drug: Amoxicillin healing phase, Drug: Placebos active phase | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): Active phase, Control, Healing phase | Intervention Type: DRUG; Name: Metronidazole active phase; Assigned to Arm(s): Active phase | Intervention Type: DRUG; Name: Metronidazole healing phase; Assigned to Arm(s): Healing phase | Intervention Type: DRUG; Name: Amoxicillin active phase; Assigned to Arm(s): Active phase | Intervention Type: DRUG; Name: Amoxicillin healing phase; Assigned to Arm(s): Healing phase | Intervention Type: DRUG; Name: Placebos active phase; Assigned to Arm(s): Control, Healing phase | Intervention Type: DRUG; Name: Placebos healing phase; Assigned to Arm(s): Active phase, Control
D: Arm Label: amoxicillin+metronidazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin, Drug: Metronidazole | Arm Label: moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): amoxicillin+metronidazole | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): amoxicillin+metronidazole | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): moxifloxacin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of a Maintenance Program for the Be Fit Employee Wellness Program at Massachusetts General Hospital
Brief Summary: This research study is being done: 1) to determine if the MGH Be Fit program helps employees to change their nutrition and exercise habits and lower their risk for chronic diseases, such as heart disease and diabetes and 2) to determine if a maintenance program following the Be Fit 12 week program will help employees to keep the positive health changes.


Options:
A: Arm Label: Control-group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control-group | Arm Label: Intervention-group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention-group | Intervention Type: BEHAVIORAL; Name: Intervention-group; Assigned to Arm(s): Intervention-group | Intervention Type: BEHAVIORAL; Name: Control-group; Assigned to Arm(s): Control-group
B: Arm Label: Internet-based maintenance program; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based maintenance program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based maintenance program; Assigned to Arm(s): Internet-based maintenance program
C: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Wellness counseling | Intervention Type: BEHAVIORAL; Name: Wellness counseling; Assigned to Arm(s): Lifestyle intervention
D: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment
Brief Summary: The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.


Options:
A: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Pioglitazone; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
D: Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE).
Brief Summary: This study is a local PCO sponsored, interventional, non-drug study to evaluate the efficacy of a health tele-counselling program in reducing cardiovascular risk in dyslipidemic patients.


Options:
A: Arm Label: WHO CVD Risk Assessment package; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WHO CVD risk assessment package | Arm Label: Health Insurance only; Type: SHAM_COMPARATOR; Interventions: Behavioral: Health Insurance only | Intervention Type: BEHAVIORAL; Name: WHO CVD risk assessment package; Assigned to Arm(s): WHO CVD Risk Assessment package | Intervention Type: BEHAVIORAL; Name: Health Insurance only; Assigned to Arm(s): Health Insurance only
B: Intervention Type: BEHAVIORAL; Name: UNITED Planned Care; Assigned to Arm(s): N/A
C: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information
D: Arm Label: COACH; Type: ACTIVE_COMPARATOR; Interventions: Other: COACH | Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention for placebo | Intervention Type: OTHER; Name: COACH; Assigned to Arm(s): COACH | Intervention Type: OTHER; Name: No intervention for placebo; Assigned to Arm(s): Standard Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding
Brief Summary: The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.


Options:
A: Arm Label: Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human albumin (Placebo) | Arm Label: Haemocomplettan® P; Type: EXPERIMENTAL; Interventions: Drug: Haemocomplettan® P | Intervention Type: DRUG; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: DRUG; Name: Human albumin (Placebo); Assigned to Arm(s): Albumin
B: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Cryoprecipitate; Type: ACTIVE_COMPARATOR; Interventions: Other: Cryoprecipitate | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: OTHER; Name: Cryoprecipitate; Assigned to Arm(s): Cryoprecipitate
C: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
D: Arm Label: Freezed-dried plasma; Type: EXPERIMENTAL; Interventions: Drug: Freezed-dried plasma | Arm Label: Fresh-frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh-frozen plasma | Intervention Type: DRUG; Name: Freezed-dried plasma; Assigned to Arm(s): Freezed-dried plasma | Intervention Type: DRUG; Name: Fresh-frozen plasma; Assigned to Arm(s): Fresh-frozen plasma

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Environmental Intervention for Weight Gain Prevention
Brief Summary: The primary aim of this research is to evaluate the efficacy of a multicomponent worksite-based, environmental intervention in reducing weight increase and obesity over time in working adults.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention
B: Arm Label: Worksite Environmental Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: weight gain prevention | Arm Label: No-contact control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: weight gain prevention; Assigned to Arm(s): Worksite Environmental Intervention
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: Behavioral: Pedometer-based intervention | Arm Label: Pedometer group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedometer-based intervention | Intervention Type: BEHAVIORAL; Name: Pedometer-based intervention; Assigned to Arm(s): Control group, Pedometer group
D: Arm Label: control (C) group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: telemedical (TM) group; Type: EXPERIMENTAL; Interventions: Device: telemedical devices (weighing machine and step counter) | Arm Label: telemedical coaching (TMC) group; Type: EXPERIMENTAL; Interventions: Device: telemedical devices (weighing machine and step counter), Behavioral: care calls once per week for 12 weeks | Intervention Type: DEVICE; Name: telemedical devices (weighing machine and step counter); Assigned to Arm(s): telemedical (TM) group, telemedical coaching (TMC) group | Intervention Type: BEHAVIORAL; Name: care calls once per week for 12 weeks; Assigned to Arm(s): telemedical coaching (TMC) group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Environmental Intervention for Weight Gain Prevention
Brief Summary: The primary aim of this research is to evaluate the efficacy of a multicomponent worksite-based, environmental intervention in reducing weight increase and obesity over time in working adults.


Options:
A: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Wellness counseling | Intervention Type: BEHAVIORAL; Name: Wellness counseling; Assigned to Arm(s): Lifestyle intervention
C: Arm Label: Tailored Physical Activity; Type: EXPERIMENTAL; Interventions: Other: Tailored Physical Activity | Arm Label: Reference group; Type: OTHER; Interventions: Behavioral: Health Counselling | Intervention Type: OTHER; Name: Tailored Physical Activity; Assigned to Arm(s): Tailored Physical Activity | Intervention Type: BEHAVIORAL; Name: Health Counselling; Assigned to Arm(s): Reference group
D: Arm Label: Worksite Environmental Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: weight gain prevention | Arm Label: No-contact control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: weight gain prevention; Assigned to Arm(s): Worksite Environmental Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-17 Follow-up of Home Visiting Intervention
Brief Summary: This study is a longitudinal follow-up of 670 primarily African-American women and their 17-year-old firstborn children enrolled since 1990 in a highly significant randomized controlled trial (RCT) of prenatal and infancy home visiting by nurses. Nurses in this program are charged with improving pregnancy outcomes, child health and development, and maternal economic self-sufficiency. This follow-up examines whether earlier program effects on maternal and child functioning lead to less violent antisocial behavior, psychopathology, substance use and use-disorders, and risk for HIV; whether these effects are greater for those at both genetic and environmental risk; and whether program effects replicate those found with whites in an earlier trial.


Options:
A: Arm Label: Accountable Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Accountable Condition | Arm Label: Control Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Accountable Condition; Assigned to Arm(s): Accountable Condition- 8 clinics | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Control Condition- 8 clinics
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promoting Parental Skills and Enhancing Attachment | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: had home visits by community workers during pregnancy | Intervention Type: BEHAVIORAL; Name: Promoting Parental Skills and Enhancing Attachment; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: had home visits by community workers during pregnancy; Assigned to Arm(s): 1
C: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral education; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral education intervention | Intervention Type: BEHAVIORAL; Name: Behavioral education intervention; Assigned to Arm(s): Behavioral education
D: Arm Label: Treatment 2: Transportation, Child Screening/Referral; Type: N/A; Interventions: N/A | Arm Label: Treatment 4: Nurse Home Visiting through Age 2; Type: N/A; Interventions: Behavioral: Nurse Home Visiting | Intervention Type: BEHAVIORAL; Name: Nurse Home Visiting; Assigned to Arm(s): Treatment 4: Nurse Home Visiting through Age 2

Answer: D